A randomized phase II study comparing capecitabine alone with capecitabine and oral cyclophosphamide in patients with advanced breast cancer-cyclox II-Reference-Cited by-同舟云学术

A randomized phase II study comparing capecitabine alone with capecitabine and oral cyclophosphamide in patients with advanced breast cancer-cyclox II

Published:2013-07 Issue:7 Volume:24 Page:1828-1834
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Harvey V.J.,Sharples K.J.,Isaacs R.J.,Jameson M.B.,Jeffery G.M.,McLaren B.R.,Pollard S.,Riley G.A.,Simpson A.B.,Hinder V.A.,Scott J.N.,Dzhelali M.V.,Findlay M.P.

Funder

Roche Products (New Zealand) Limited

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/24/7/1828/466871/mdt065.pdf

Reference43 articles.

1. Randomised, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer;O'Shaughnessy;Ann Oncol,2001

2. Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines;Talbot;Br J Cancer,2002

3. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer;Stockler;J Clin Onol,2011